Skip to main content
Literatur
1.
Zurück zum Zitat Casanova J, Bonagura V. J Clin Immunol. 2018;38(4):445–6. Casanova J, Bonagura V. J Clin Immunol. 2018;38(4):445–6.
2.
Zurück zum Zitat Picard C, Gaspar BH, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.CrossRef Picard C, Gaspar BH, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. J Clin Immunol. 2018;38(1):96–128.CrossRef
3.
Zurück zum Zitat Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRef Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. J Clin Immunol. 2018;38(1):129–43.CrossRef
4.
Zurück zum Zitat Queiroz-Telles F, Mercier T, Maertens J, Sola CBS, Bonfim C, Lortholary O, et al. Successful allogenic stem cell transplantation in patients with inherited CARD9 deficiency. J Clin Immunol. 2019;39(5):462–9.CrossRef Queiroz-Telles F, Mercier T, Maertens J, Sola CBS, Bonfim C, Lortholary O, et al. Successful allogenic stem cell transplantation in patients with inherited CARD9 deficiency. J Clin Immunol. 2019;39(5):462–9.CrossRef
5.
Zurück zum Zitat Shouval DS, Kowalik M, Snapper SB. The treatment of inflammatory bowel disease in patients with selected primary immunodeficiencies. J Clin Immunol. 2018;38(5):579–88.CrossRef Shouval DS, Kowalik M, Snapper SB. The treatment of inflammatory bowel disease in patients with selected primary immunodeficiencies. J Clin Immunol. 2018;38(5):579–88.CrossRef
6.
Zurück zum Zitat Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017;37(4):351–6.CrossRef Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). J Clin Immunol. 2017;37(4):351–6.CrossRef
7.
Zurück zum Zitat Georgiev P, Charbonnier L-M, Chatila TA. Regulatory T cells: the many faces of Foxp3. J Clin Immunol. 2019;39(7):623–40.CrossRef Georgiev P, Charbonnier L-M, Chatila TA. Regulatory T cells: the many faces of Foxp3. J Clin Immunol. 2019;39(7):623–40.CrossRef
8.
Zurück zum Zitat Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.CrossRef Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. J Clin Immunol. 2019;39(6):532–56.CrossRef
9.
Zurück zum Zitat Pöyhönen L, Bustamante J, Casanova J-L, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRef Pöyhönen L, Bustamante J, Casanova J-L, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. J Clin Immunol. 2019;39(4):376–90.CrossRef
10.
Zurück zum Zitat Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019;39(3):277–86.CrossRef Booshehri LM, Hoffman HM. CAPS and NLRP3. J Clin Immunol. 2019;39(3):277–86.CrossRef
11.
Zurück zum Zitat Tangye SG, Bier J, Lau A, Nguyen T, Uzel G, Deenick EK. Immune dysregulation and disease pathogenesis due to activating mutations in PIK3CD—the Goldilocks’ effect. J Clin Immunol. 2019;39(2):148–58.CrossRef Tangye SG, Bier J, Lau A, Nguyen T, Uzel G, Deenick EK. Immune dysregulation and disease pathogenesis due to activating mutations in PIK3CD—the Goldilocks’ effect. J Clin Immunol. 2019;39(2):148–58.CrossRef
12.
Zurück zum Zitat Delmonte OM, Schuetz C, Notarangelo LD. RAG deficiency: two genes, many diseases. J Clin Immunol. 2018;38(6):646–55.CrossRef Delmonte OM, Schuetz C, Notarangelo LD. RAG deficiency: two genes, many diseases. J Clin Immunol. 2018;38(6):646–55.CrossRef
13.
Zurück zum Zitat Corvilain E, Casanova J-L, Puel A. Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults. J Clin Immunol. 2018;38(6):656–93.CrossRef Corvilain E, Casanova J-L, Puel A. Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults. J Clin Immunol. 2018;38(6):656–93.CrossRef
14.
Zurück zum Zitat Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38(5):558–68.CrossRef Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. J Clin Immunol. 2018;38(5):558–68.CrossRef
15.
Zurück zum Zitat Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569–78.CrossRef Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569–78.CrossRef
16.
Zurück zum Zitat Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. J Clin Immunol. 2018;38(1):13–27.CrossRef Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. J Clin Immunol. 2018;38(1):13–27.CrossRef
17.
Zurück zum Zitat Gallo V, Cirillo E, Giardino G, Pignata C. FOXN1 deficiency: from the discovery to novel therapeutic approaches. J Clin Immunol. 2017;37(8):751–8.CrossRef Gallo V, Cirillo E, Giardino G, Pignata C. FOXN1 deficiency: from the discovery to novel therapeutic approaches. J Clin Immunol. 2017;37(8):751–8.CrossRef
18.
Zurück zum Zitat Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. J Clin Immunol. 2017;37(7):626–37.CrossRef Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. J Clin Immunol. 2017;37(7):626–37.CrossRef
19.
Zurück zum Zitat Boisson B, Puel A, Picard C, Casanova J-L. Human IκBα gain of function: a severe and syndromic immunodeficiency. J Clin Immunol. 2017;37(5):397–412.CrossRef Boisson B, Puel A, Picard C, Casanova J-L. Human IκBα gain of function: a severe and syndromic immunodeficiency. J Clin Immunol. 2017;37(5):397–412.CrossRef
20.
Zurück zum Zitat Klein C. Kostmann’s disease and HCLS1-associated protein X-1 (HAX1). J Clin Immunol. 2017;37(2):117–22.CrossRef Klein C. Kostmann’s disease and HCLS1-associated protein X-1 (HAX1). J Clin Immunol. 2017;37(2):117–22.CrossRef
21.
Zurück zum Zitat Meyts I. Hematopoietic stem cell transplantation in CARD9 deficiency: knight in shining armor? J Clin Immunol. 2019;39(5):459–61.CrossRef Meyts I. Hematopoietic stem cell transplantation in CARD9 deficiency: knight in shining armor? J Clin Immunol. 2019;39(5):459–61.CrossRef
22.
Zurück zum Zitat Bonagura VR. Successful rituximab treatment for lymphoma, secondary immunodeficiency causing debilitating sinusitis: underlying primary immunodeficiency disease, and alternative treatments to improve the quality of life? J Clin Immunol. 2019;39(3):229–30.CrossRef Bonagura VR. Successful rituximab treatment for lymphoma, secondary immunodeficiency causing debilitating sinusitis: underlying primary immunodeficiency disease, and alternative treatments to improve the quality of life? J Clin Immunol. 2019;39(3):229–30.CrossRef
23.
Zurück zum Zitat Aiuti A, Quinti I. In Memoriam: Fernando Aiuti, MD (June 8, 1935–January 9, 2019). J Clin Immunol. 2019;39(2):142–3.CrossRef Aiuti A, Quinti I. In Memoriam: Fernando Aiuti, MD (June 8, 1935–January 9, 2019). J Clin Immunol. 2019;39(2):142–3.CrossRef
24.
Zurück zum Zitat Lankester A, Heidt P, Rümke H, Bredius R, van Tol M. In Memoriam: Prof. Dr. J.M.J.J. Vossen (1937-2019). J Clin Immunol. 2019;39(6):530–1.CrossRef Lankester A, Heidt P, Rümke H, Bredius R, van Tol M. In Memoriam: Prof. Dr. J.M.J.J. Vossen (1937-2019). J Clin Immunol. 2019;39(6):530–1.CrossRef
25.
Zurück zum Zitat Condino-Neto A. Prof. Dr. Beatriz Tavares Costa-Carvalho Obituary. J Clin Immunol. 2019;39(6):529.CrossRef Condino-Neto A. Prof. Dr. Beatriz Tavares Costa-Carvalho Obituary. J Clin Immunol. 2019;39(6):529.CrossRef
26.
Zurück zum Zitat Crow YJ, Lebon P, Casanova J-L, Gresser I. A brief historical perspective on the pathological consequences of excessive type I interferon exposure in vivo. J Clin Immunol. 2018;38(6):694–8.CrossRef Crow YJ, Lebon P, Casanova J-L, Gresser I. A brief historical perspective on the pathological consequences of excessive type I interferon exposure in vivo. J Clin Immunol. 2018;38(6):694–8.CrossRef
Metadaten
Titel
Editorial, Journal of Clinical Immunology
verfasst von
Jean-Laurent Casanova
Vincent Bonagura
Publikationsdatum
15.10.2019
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 8/2019
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-019-00699-0

Weitere Artikel der Ausgabe 8/2019

Journal of Clinical Immunology 8/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.